Goleta, California.-(Business Wire) -Inogen, Inc. (NASDAQ: Ingn), a medical technology company that offers innovative respiratory products for use in homecare settings, announced today that it has entered a strategic cooperation with Jiangsu UU Treatment ,
Strategic cooperation through distribution of certain respiratory products in the United States (NASDAQ 🙂 is expected to broaden and select other areas, expand and increase the inogen’s inogen through R&D cooperation , And accelerate the entry of the brand of innocent. Chinese market. In addition, Uwell has agreed to invest around $ 27.2 million in innocent, 9.9% normal equity represents interest, further supports cooperation and increases the balance sheet of the inno. .
Cooperation with Yuvale is an important step in intensifying the development trajectory of the innocent. Kevin Smith, Chairman and Chief Executive Officer said that by increasing our product portfolio, global appearance and our innovation pipeline, we hope to be well deployed to catch new market opportunities. This cooperation supports our commitment to give our shareholders a long-term value and confirms our vision of establishing innocent as a platform for the best-in-in-class respiratory solution for patients around the world. We are confident that our cooperation with Uwell will play an important role in our continuous success. ,
“Innocent is a leader in the respiratory medicine market and our strategic cooperation provides the ability to broaden its geographical access and meet the needs of the patient worldwide,” said Alex Wu said. Uwell shares innocent’s commitment to develop and provide innovative, quality products and we believe that together we can create a meaningful difference in the life of respiratory patients. Together, the purpose of Yule and innocent is to define the next generation of respiratory products.
The cooperation agreement will be effective immediately, while the purchase of equity from the inrogen is expected to be closed during the first quarter of 2025, subject to some customary closing conditions.
About innocent
Inogen, Inc. (NASDAQ: Ingn) is a major global medical technology company that offers innovative respiratory products for use in homecare settings. Inquenge supports patient respiratory care by developing, manufacturing and marketing the innovative best-in-in-class respiratory medicine devices used to take care of patients suffering from chronic respiratory conditions. Initiative partners with patients, prescriptions, home medical equipment providers and distributors to provide their respiratory medicine products widely, giving patients a chance to manage the effects of their disease.
For more information, please visit www.inogen.com.
Inquenge has used, and intends to continue using it, its investor relationship website, http://investor.inogen.com/, content disclosure non-public information and compliance with its disclosure obligations under regulation FD For.
About youth
Since its establishment in 1998, the Ulew has been at the forefront of increasing the care of the patient and providing state -of -the -art medical equipment solutions to enhance the care of the patient and improve home healthcare. Yuwell (002223.SZ) produced more than the revenue of US $ 1 billion in 2023, and is a comprehensive product portfolio in respiratory treatment, diabetes management, electronic diagnostics products, first aid solution and rehabilitation.
With a stable commitment to clinical excellence, the Uwell distributes high quality, therapeutic reliable products that empower health professionals to achieve better patient results.
With 9 state -of -the -art R&D centers and 7 advanced production features, the global presence of Uwells extends over 100 countries and supports over 300,000 healthcare institutions. The Uvell touches the lives of patients around the world by bringing professional, user -friendly medical devices.
forward-looking statements
This press release includes the forward -looking statements within the meaning of the 1995 Private Securities Litigation Reforms Act. All statements contained in this communication which are not historical facts, including, but are not limited, innocent business plans, statements about market opportunities, market opportunities, market opportunities, market opportunities, market opportunities, market opportunities, market opportunities, market opportunities, market opportunities, market opportunities, market opportunities, market opportunities There are opportunities, market opportunities, market opportunities, financial approaches, development strategies, and anticipated operational results, further visible statements. Words such as AIMS, confidence, estimation, plan, expectation, will, intention, potential, potential, and similar expressions are to identify forward -looking statements. Forward-loving statements are subject to many risks and uncertainties, which can lead to physically different from the currently anticipated results, including, but it is not limited, related to risks and uncertainties, which are related to the eloques Along with the potential benefits of the cooperation of the innocent; Satisfaction of terms of terms under the Securities Purchase Agreement related to equity investment; Time of closing of equity investment; Market acceptance of your products; Competition; Its sales, marketing and distribution capabilities; Its employed sales, marketing and research and development activities; And risk associated with international operations. For detailed discussion of these and other risks that can affect the operation and financial performance of innocents, please see the risk factors section of your annual report at Form 10-K for the end of December 31, 2023, Form Its quarterly report on 10- Q for the calendar quarter Q ends on March 31, 2024 and in its other filing with the Securities and Exchange Commission. These forward -looking statements speak only as this date. Innocent reveals any obligation to update in forward-loving statements, except law.
See source version on businesswire.com: https://www.businesswire.com/news/news/home/20250126900450/en/
ir@inogen.net
Source: Inquenge, Inc.
